About Enveric Biosciences, Inc. - Common Stock (ENVB)
Enveric Biosciences is a biotechnology company focused on developing innovative therapies for various mental health conditions and neurological disorders. The company leverages its expertise in cannabinoid science and psychedelic research to explore novel treatment options, aiming to address significant unmet healthcare needs. By combining advanced technology with a commitment to scientific rigor, Enveric seeks to deliver safer and more effective solutions that can improve patient outcomes and enhance the quality of life for individuals suffering from these challenging conditions. Read More
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 shares of common stock originally issued in February 2025, having an exercise price of $3.00 per share, at a reduced exercise price of $0.915 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-284277). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.2 million, prior to deducting placement agent fees and estimated offering expenses.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the publication of two peer-reviewed research papers describing innovative bioproduction strategies for creating therapeutic compounds. While Enveric’s lead candidate EB-003 is manufactured using established synthetic chemistry methods common to the pharmaceutical industry, these publications highlight the Company’s broader scientific leadership in pioneering bioproduction approaches that expand the tools available for drug discovery. The papers were published in ACS Chemical Biology and BioDesign Research.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) to its request for a Pre-Investigational New Drug (pre-IND) Type B meeting for its lead program, EB-003.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the relocation of its corporate headquarters to Cambridge, Massachusetts, 02142.
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression, post-traumatic stress disorder (PTSD), and other neuropsychiatric disorders, today announced the successful completion of 7-day Dose Range Finding (DRF) toxicology studies in two preclinical species for its lead drug candidate, EB-003. The results define the Maximum Tolerated Dose (MTD) and represent a key pipeline advancement landmark supporting the Company’s IND-enabling activities and preparation for First-in-Human clinical trials.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced positive results in a preclinical, exposure-based therapeutic model for post-traumatic stress disorder (PTSD).
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today unveiled additional data indicating that its lead development candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, in addition to its other previously disclosed receptor engagement activities. The 5-HT1B receptor is a recognized therapeutic target for treating several central nervous system (“CNS”) conditions, including major depressive disorder, Parkinson’s disease, migraines, and cluster headaches.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced the issuance of a new U.S. patent (USPTO Number 12,187,679). The patent strengthens Enveric’s intellectual property portfolio and covers a structurally diverse class of novel molecules with potential therapeutic applications in the treatment of sleep and central nervous system (CNS) disorders.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced positive preclinical results for its lead neuroplastogen drug candidate, EB-003, in the Open Space Forced Swim Test, a preclinical mouse model of severe depression and despair.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules discovered to offer potential to address neurodegenerative disease. If confirmed through further testing, the potential of this newly identified group of molecules expands the market potential for Enveric drug candidates in a new direction.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update following the filing of its 10-K on Friday March 28, 2025 which reported financial results for the fourth quarter and year ended December 31, 2024.
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring®, which is being held in Milan, Italy, March 17-19, 2025.
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company will build on its recent business development momentum by soliciting Requests-For-Proposal (“RFPs”) for license or sale of its PsyAI™ trademark portfolio as a means of maximizing value for an asset which is no longer strategic given the Company’s focus on drug development. This limited portfolio of US and Canadian trademark assets is held by its subsidiary, Enveric Biosciences Canada, Inc. Enveric has already received two expressions of interest in the licensing or sale of the portfolio of PsyAI™ marks, which has jump-started the RFP process for auctioning the marks.
